The Technical Analyst
Ultimovacs ASA [ULTI.OL]
Exchange: OSE Sector: Healthcare Industry: Biotechnology
Ultimovacs ASA Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.29% NOK6.98
Europe/Oslo / 30 apr 2024 @ 16:26
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 240.09 mill |
| EPS: | -5.50 |
| P/E: | -1.270 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 34.40 mill |
| Avg Daily Volume: | 1.534 mill |
| RATING 2024-04-30 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.270 | sector: PE 57.61 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.270 | industry: PE -0.482 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
NOK7.64 (9.47%) NOK0.661 |
| Date: 2024-04-30 |
| Expected Trading Range (DAY) |
|---|
|
NOK 2.51 - 11.45 ( +/- 64.00%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 15:51 - NOK7.08
Forecast 2: 16:00 - NOK7.08
Forecast 3: 16:00 - NOK7.08
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | NOK6.98 (0.29% ) |
| Volume | 0.309 mill |
| Avg. Vol. | 1.534 mill |
| % of Avg. Vol | 20.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ULTI.OL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:42 | sell | NOK130.80 | N/A | Active |
|---|
ULTI.OL
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.